Blog

Now that Funo Biotech is also entering the cell and gene CDMO space, could it be following the same path as the antibody industry?

Release Date:

2023-03-27 17:48

Following the spin-off of an antibody biopharmaceutical company CMC Established independently from the production team CDMO Following the company, cell and gene therapy R&D entities have also been spun off to form independent companies. CGT CDMO the trend, for example, there is AAV Drug development company Jia Yin Bio has 2022 Established in the year AAV CDMO Service company Xingcheng Bio ( CoJourney ), the oncolytic virus drug R&D company FunoGene Biotech has recently established FuzhenNa Biotech ( FRASERNA), Providing viral vector drugs and nucleic acid drugs from concept to India and a one-stop solution for commercialization CRDMO Service platform.

Jia Yin Bio Since 2019 Since its establishment, the company has been focused on the R&D of AAV viral vector products for gene therapy. The first gene therapy EXG001-307 For Type 1 Spinal Muscular Atrophy (Type 1 SMA) received NMPA IND in June 2022, concurrently with EXG102-031. Ophthalmic Injection for Wet Age-Related Macular Degeneration (wAMD) It is Jia Yin Bio’s second drug, Meizhong. IND. According to the financing disclosure, the company has completed four rounds of funding totaling over RMB 100 million, with investors including Hillhouse Capital and Junlian Capital. , Temasek A renowned institution under Temasek.

FunoJian Bio Since 2015 Founded in [year], with operations in Canada, China, and the United States. 170 Multiple employees, whose team has over… in basic research, translational studies, and clinical development in immunotherapy and oncolytic virus therapy. 25 Years of experience .2020 year 10 The Yue, FunoGene Global R&D Industrial Center is a modern, integrated biopharmaceutical innovation park invested in and developed by FunoGene Biotechnology Co., Ltd., bringing together R&D, pilot-scale production, corporate headquarters offices, and supporting residential amenities. It covers the discovery and early-stage research of viral vector-based drugs and nucleic acid therapeutics, as well as small-scale pilot production and Good Manufacturing Practice Pilot-scale production and associated supporting and auxiliary facilities. The project is located in Nanxiang Town, Jiading District, Shanghai, with a planned land area of 13430.5 square meters, with a total floor area of approximately 33442.84 square meters. The project was 2021 year 9 month 25 Official construction commenced on [date], with an expected completion date of [date]. 2023 Construction was completed and the facility was put into operation in the first quarter of the year. Following commissioning, pilot-scale production of nucleic acid vaccine drugs is expected to commence. 200 10,000 doses per year, viral vector drugs 1000 Ten thousand doses per year. According to the financing disclosure, 2021 In less than a year, the company has completed three rounds of financing, totaling over 2.6 One hundred million US dollars.

During market upturns, biopharmaceutical R&D companies benefit from low financing costs and high valuations, making them prime targets for local government parks seeking to attract investment and expand operations—resulting in land allocations and infrastructure development. However, when the broader macro environment shifts rapidly, with R&D pipelines advancing more slowly than expected and financing costs rising as valuations decline, these companies are forced to adopt strategic retrenchment and may need to divest certain business units to establish CDMO Generate cash flow.


 

(Reposted from E-Pharmacy Barometer )

Previous page

Is there a bubble in China’s cell and gene therapy industry?

The EBC Expo is a showcase for the bioindustry.

Next page

Related News

(II) Security Assurance Section | Safety First, Defense Prioritized

Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.

(1) Compliance and Traceability Section | Establishing a Foundation of Compliance, Ensuring Source Tracing

This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.

Compliance as the Foundation, Safety as the Core | The Steadfast Commitment and Confidence Behind Heyou Sheng’s Serum Substitute

In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.

A novel mechanism by which iron overload in the tumor microenvironment triggers ferroptosis in CD8⁺ T cells | Guangzhou National Laboratory publishes in Nature Communications, revealing a key pathway of immune evasion (IF: 18.2)

Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.

Hycells Recruitment | Never Stop Exploring, Never Stop Innovating

The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.

3.0 High-Efficiency Version of HiXpan® NK Serum-Free Culture Kit | Chapter 4: Comprehensive Overview of Customer-Specific Culture Data Across Multiple Scenarios

The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.